Dong Wei

Dong Wei

Auto-generated profile, based on publicly available information

Dong Wei

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
LGLingxi Guo
Lingxi Guo
DWDong Wei
Dong Wei
XZXinxin Zhang
Xinxin Zhang
YWYurong Wu
Yurong Wu
QLQingyun Li
Qingyun Li
Jie Ming QuJie Ming Qu
Jie Ming Qu
Objective: The aim of this study was to further clarify clinical characteristics and predict mortality risk among patients with viral pneumonia. Methods: A total of 528 patients with viral pneumonia at RuiJin hospital in Shanghai from May 2015 to May 2019 were recruited. Multiplex real-time RT-PCR was used to detect respiratory viruses. Demographic information, comorbidities, routine laboratory examinations, immunological indexes, etiological detections, radiological images and treatment were collected on admission. Results: 76 (14.4%) patients died within 90 days in hospital. A predictive MuLBSTA score was calculated on the basis of a multivariate logistic regression model in order to predict mortality with a weighted score that included multilobular infiltrates (OR = 5.20, 95% CI 1.41–12.52, p = 0.010; 5 points), lymphocyte ≤ 0.8∗109/L (OR = 4.53, 95% CI 2.55–8.05, p < 0.001; 4 points), bacterial coinfection (OR = 3.71, 95% CI 2.11–6.51, p < 0.001; 4 points), acute-smoker (OR = 3.19, 95% CI 1.34–6.26, p = 0.001; 3 points), quit-smoker (OR = 2.18, 95% CI 0.99–4.82, p = 0.054; 2 points), hypertension (OR = 2.39, 95% CI 1.55–4.26, p = 0.003; 2 points) and age ≥60 years (OR = 2.14, 95% CI 1.04–4.39, p = 0.038; 2 points). 12 points was used as a cut-off value for mortality risk stratification. This model showed sensitivity of 0.776, specificity of 0.778 and a better predictive ability than CURB-65 (AUROC = 0.773 vs. 0.717, p < 0.001). Conclusion: Here, we designed an easy-to-use clinically predictive tool for assessing 90-day mortality risk of viral pneumonia. It can accurately stratify hospitalized patients with viral pneumonia into relevant risk categories and could provide guidance to make further clinical decisions.

4 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XYXiaoqi Yu
Xiaoqi Yu
DWDong Wei
Dong Wei
WXWenxin Xu
Wenxin Xu
CLChuanmiao Liu
Chuanmiao Liu
WGWentian Guo
Wentian Guo
ECEr-zhen Chen
Er-zhen Chen
The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the generation of variants that may diminish host immune responses to vaccine formulations. Here we show a registered observational clinical trial (NCT04795414), we assess the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine BBIBP-CorV in a cohort of 1006 vaccine recipients. No serious adverse events are observed during the term of the study. Detectable virus-specific antibody is measured and determined to be neutralizing in 698/760 (91.84%) vaccine recipients on day 28 post second vaccine dose and in 220/581 (37.87%) vaccine recipients on day 180 post second vaccine dose, whereas vaccine-elicited sera show varying degrees of reduction in neutralization against a range of key SARS-CoV-2 variants, including variant Alpha, Beta, Gamma, Iota, and Delta. Our work show diminished neutralization potency against multiple variants in vaccine-elicited sera, which indicates the potential need for additional boost vaccinations.

23 October 2018 in Emerging Microbes & Infections
Verified
Journal Article
Open access
DWDong Wei
Dong Wei
DYDe-Ming Yu
De-Ming Yu
MWMing-Jie Wang
Ming-Jie Wang
DZDong-Hua Zhang
Dong-Hua Zhang
QCQi-Jian Cheng
Qi-Jian Cheng
XZXinxin Zhang
Xinxin Zhang
Seasonal H3N2 influenza viruses are recognized as major epidemic viruses, exhibiting complex seasonal patterns in regions with temperate climates. To investigate the influence of viral evolution an...

1 January 2020 in Emerging Microbes & Infections
Verified
Journal Article
Open access
XYXiaoqi Yu
Xiaoqi Yu
DWDong Wei
Dong Wei
YCYongyan Chen
Yongyan Chen
DZDonghua Zhang
Donghua Zhang
XZXinxin Zhang
Xinxin Zhang
Since the first report of the coronavirus disease (COVID-19) in late December 2019, the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now widely spread to more than 187 countries and regions. However, it is unclear whether there has been cryptic transmission before these early officially confirmed cases, we therefore retrospectively screened for the SARS-CoV-2 RNA in 1271 nasopharyngeal swab samples, as well as the prevalence of IgM, IgG, and total antibodies against SARS-CoV-2 in 357 matched serum samples collected from hospitalized patients with influenza-like illness between 1 December 2018 and 31 March 2020 in Shanghai Ruijin Hospital. The onset date of the earliest COVID-19 case in this study was 25 January 2020. Before this time point, the presence of SARS-CoV-2 was not observed, which limited the possibility that SARS-CoV-2 has already spread among the population before the large-scale outbreak. Additionally, among 6662 patients with influenza-like illness from 1 December 2017 to 31 March 2020, the overall number of patients positive for influenza and other respiratory viruses during the COVID-19 period decreased significantly when compared with that in the same period of the last two years, reflecting that public health interventions can effectively control the spread of common respiratory viruses.

26 October 2022 in Emerging Microbes & Infections
Verified
Journal Article
Open access
DWDong Wei
Dong Wei
YCYingying Chen
Yingying Chen
XYXiaoqi Yu
Xiaoqi Yu
YLYang-Dian Lai
Yang-Dian Lai
WXWenxin Xu
Wenxin Xu
YWYing Wang
Ying Wang
BBIBP-CorV exerts efficient protection against SARS-CoV-2 infection. However, waning vaccine-induced humoral immune responses after two-dose vaccination have significantly undermined durable immuno-protection. In this study, we have demonstrated that although anti-spike (S) antibody responses in BBIBP-CorV vaccinees exhibited three serotypes after 6 months, including de novo sero-negative, sero-positive, and sero-decay features, S-specific interferon-γ release as well as Th1 cytokine production in CD4+ and CD8+ T cells were comparable, especially in vaccinees without detectable neutralizing antibodies. Notably, regardless of dramatic increases in humoral immunity after booster vaccination, T cell responses targeting S protein from either wild type or Omicron remained stable before and after booster vaccination in all three serotype vaccinees. No severe cases were observed even in the sero-decay group during the Omicron epidemic in Shanghai. Our results thus illustrate that unlike fluctuating humoral responses, viral-specific T cell responses are extremely stable after booster vaccination. Sustained T cell responses might be dedicated to the rapid restoration of antibody responses after booster vaccination.

27 October 2026 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
AFAnqi Feng
Anqi Feng
WTWei Tan
Wei Tan
WXWenxin Xu
Wenxin Xu
XZXinxin Zhang
Xinxin Zhang
DWDong Wei
Dong Wei
ZYZhitao YANG
Zhitao YANG
Background: Antivirals are widely used to treat influenza, but potential resistance mutations remain a major challenge, and clinical data on key resistance mutations are limited. Methods: We conducted a retrospective cohort study of 765 adults with RT‐PCR‐confirmed influenza A admitted to Ruijin Hospital, Shanghai, between 2019 and 2024 to determine whether specific NA/PA mutations are associated with severe outcomes or prolonged length of stay (LOS) when analyzed alongside key host factors. PA and NA sequences were obtained and linked to the clinical cohort for mutation‐clinical outcome analyses. Multiple testing was addressed by controlling the false discovery rate using the Benjamini–Hochberg procedure. Results: Among 765 inpatients with influenza A virus infection, the median age was 68 years; 5.0% were severe disease and 9.9% died. Older age, higher CURB‐65 score, and bacterial/fungal co‐infection were the main correlates of mortality, whereas antiviral regimen and Ct value were not independently associated with mortality or severe outcomes. Adjusted observational analyses showed a lower estimate for severe disease with baloxavir but no association with in‐hospital death. Major high‐level resistance mutations were absent; detected NA/PA mutations showed no robust association with severe disease or mortality. PA‐F105L showed an exploratory association with longer LOS, but this finding was attenuated after adjustment and was confounded by clade and calendar period. Conclusions: Clinical outcomes were driven mainly by host factors and admission severity. Detected NA/PA mutations were not robustly associated with severe outcomes, while high‐level resistance could not be assessed; PA‐F105L–LOS association requires phenotypic and external validation.